*AI or fulvestrant.
†MONALEESA-2: At median 80-month follow-up, KISQALI® + AI achieved mOS of 63.9 months vs. 51.4 months with placebo + AI (HR 0.76; 95% CI: 0.63–0.93; p=0.008). MONALEESA-3: At median 71-month follow-up, KISQALI® + fulvestrant achieved mOS of 67.6 months vs. 51.8 months with placebo + fulvestrant (HR 0.67; 95% CI: 0.50–0.9). MONALEESA-7: At median 54-month follow-up, KISQALI® + AI achieved mOS of 58.7 months vs. 47.7 months with placebo + AI (HR 0.8; 95% CI: 0.62–1.04). OS benefit in the prespecified 2^nd interim analysis: HR 0.70; 95% CI: 0.50–0.98.^1–4
Advanced or Metastatic Breast Cancer
KISQALI® is indicated for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with:
• an aromatase inhibitor as initial endocrine-based therapy; or
• fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy. 
aBC, advanced breast cancer; AI, aromatase inhibitor; CI, confidence interval; ET, endocrine therapy; HER2-, human epidermal growth factor receptor 2 negative; HR, hazard ratio; HR+, hormone receptor positive; LHRH, luteinising hormone-releasing hormone; mOS, median overall survival; OS, overall survival.